Abstract:HomeHypertensionVol. 67, No. 2A Woman With Treatment-Resistant Hypertension Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toSupplemental MaterialFree AccessResearch ArticlePDF/EPUBA Woman With Treatment-Resistant Hypertension Gemma Currie, Christian Delles, Rhian M. Touyz, Jan A. Staessen, Anna F. Dominiczak, Garry L.R. Jennings and Ji-Guang Wang Gemma CurrieGemma Currie From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author , Christian DellesChristian Delles From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author , Rhian M. TouyzRhian M. Touyz From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author , Jan A. StaessenJan A. Staessen From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author , Anna F. DominiczakAnna F. Dominiczak From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author , Garry L.R. JenningsGarry L.R. Jennings From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author and Ji-Guang WangJi-Guang Wang From the Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom (G.C., C.D., R.M.T., A.F.D.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium (J.A.S.); Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia (G.L.R.J.); and Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (J.-G.W.). Search for more papers by this author Originally published28 Dec 2015https://doi.org/10.1161/HYPERTENSIONAHA.115.06756Hypertension. 2016;67:243–250Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2015: Previous Version 1 Presentation of CaseAlthough this is not a particularly unusual or rare case of hypertension, it highlights the challenges we have as clinicians in managing such patients. The patient, a 60 year-old woman, was referred to the tertiary blood pressure clinic at Glasgow’s Western Infirmary 5 years ago by a consultant cardiologist for management of resistant hypertension. This lady has a vasculopathy with ongoing intermittent claudication and had previous bilateral superficial femoral artery occlusions on a background of hypercholesterolemia and a significant smoking history. The patient has problematic underlying ischemic heart disease, having had angina since 2001, numerous percutaneous interventions, and a 2-vessel coronary artery bypass graft. Despite this, she had a non–ST-segment–elevation myocardial infarction (MI) 2 years before presentation.Blood pressure at first visit to the clinic was 182/106 mm Hg despite numerous antihypertensive medications, including an angiotensin-converting enzyme inhibitor, calcium channel blocker, 2 different diuretics, α-blocker, and β-blocker in addition to her antianginal and secondary preventative medications (Table). Review of case notes and previous clinic documentation revealed that clinic blood pressure was elevated for at least 10 years with systolic readings ranging from 150 to 200 and diastolic between 90 and 100 mm Hg.Table. Total Daily Dose of Antihypertensive Medications: An Overview of Antihypertensive Medication at the Time of Referral to the Clinic (2010), Before RDN (2012) and Immediately After RDN (2012), and in 2015Medication20102012 Before RDN2012 After RDN2015Nifedipine XL, mg90903030Ramipril, mg510……Bendroflumethiazide, mg2.52.5……Furosemide, mg40804020Bisoprolol, mg10102.5…Doxazosin, mg816……Spironolactone, mg…25……RDN indicates renal denervation.The patient was admitted to the investigation ward for a week of workup. During this time, routine biochemistry showed normal renal function and electrolytes. Urine albumin/creatinine ratio was within the microalbuminuric range at 4.2 mg/mmol. Cardiac and mediastinal contours seemed normal on chest x-ray, and neither ECG nor echocardiogram showed significant left ventricular hypertrophy (LVH). No biochemical evidence to suggest pheochromocytoma or primary aldosteronism was found. Renal ultrasound exhibited 2 normal sized nonobstructed kidneys with no evidence of cortical thinning, and magnetic resonance angiography displayed normal renal vasculature with no evidence of renal artery stenosis. The patient also had an isotope renogram that displayed normal tracer uptake, excretion, and drainage and revealed that both kidneys were contributing equally to renal function.Further Investigations?Professor Christian Delles: I want to take the opportunity to go through the list of medications again (Table); she is on a large number of antihypertensive agents. Treatment-resistant hypertension is commonly defined as being uncontrolled with a blood pressure of >140/90 mm Hg despite ≥3 antihypertensive agents of which one should be a diuretic. So, the patient fulfills the criteria for resistant hypertension.There are many epidemiological studies on the prevalence of resistant hypertension. The majority agree that 8% to 10% of the hypertensive population are treatment resistant,1 but this may also be a discussion point from your own experience: how many patients do we really see with this condition? It is quite typical that these patients are often already on a large number of drugs when they are referred to us as specialists. The European Society of Hypertension guideline chart shows a number of combination therapies that are recommended, and I think most of the treatment-resistant patients that we see have all of these drugs already.2 However, when we look beyond, the treatment that is usually recommended the guidelines are very, very vague. For example, if you look at the European Society of Hypertension guidelines, you do not find a lot of drugs that are named for treatment options of resistant hypertension or for hypertension where the first-, second-, or third-line treatment does not work anymore.2Of the possible fourth- or fifth-line therapies available, the one drug that stands out is spironolactone because there is reasonable trial evidence demonstrating benefit, albeit from small studies. For example, an analysis of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) data showed that addition of spironolactone to the usual antihypertensive medication reduced blood pressure significantly.3 Spironolactone is suggested in many guidelines, but the guidelines do not mention much about any other antihypertensive agents that we may consider. There is also some development of new antihypertensive drugs, but it is probably fair to say that none of them has really reached the market yet.4 So, I think at the moment, we need to work with what is available.Professor Rhian Touyz: We have here a very interesting patient who has presented with resistant hypertension. She is on the classical drugs that we would expect based on the guidelines. I have some questions, but at this point, we will open the questions to the floor.Professor Jan Staessen: First of all, why was this patient on a thiazide diuretic plus a loop diuretic? The second question is I don’t know the normal values of renin in your lab but if a patient is on ramipril, a thiazide diuretic and a loop diuretic, what you would expect is an increase in renin activity if the patient is adherent, even if she is taking a β-blocker. So, please inform us on the range of renin values in your lab and whether it was elevated, normal, or low. The third question, I think the most important one, I have not seen ambulatory blood pressure and that is the gold standard. These days you cannot diagnose, treat, or manage any patient with hypertension or referred for hypertension without ambulatory blood pressure monitoring.Dr Gemma Currie: Your point on ambulatory blood pressure monitoring is absolutely correct and that will be presented in the next phase of discussion. From the point of view of medication, we are not saying this is an example of the gold standard way to manage a case. I think there was potentially an element of “too many cooks” since this woman was also attending a number of secondary and tertiary referral clinics with everyone making adjustments to her medication. That is probably the reason for some counter intuitive treatment decisions.Professor Delles: The renin levels were in the normal range. It is probably worth discussing how much we can interpret these results. I fully agree with you that a number of these drugs should have increased the renin, on the other hand, she was on a β-blocker as you quite rightly said. I’m not sure if we really have hard data to say how to interpret plasma renin if someone is on an angiotensin receptor blocker, a diuretic and a β-blocker.Professor Anna Dominiczak: I have a related question. I am worried that a woman with such high blood pressure presumably for a considerable amount of time has no LVH at all, and I still worry about adherence. I have been very taken by a talk given yesterday by Professor Bryan Williams where they showed that people on 6 drugs are 100% nonadherent. So, does she really have resistant hypertension or is it a case of well-covered “I always take my tablets, doctor” type of noncompliant, nonadherent patient. Please persuade me.Professor Delles: We will discuss the adherence issue in a minute, and we certainly had the same queries as yourself.There is organ damage in this lady: she has had MIs and has peripheral artery disease. So, I would not agree that she has a falsely high blood pressure and no organ damage just because we didn’t find LVH. So, how far do we rely on these typical organ damages like renal failure, increased albumin/creatinine ratio, and LVH? Would we not say that this patient also has hypertensive organ damage already because she had an MI?Dr Pervaiz Iqbal: My question is about compliance, and this particular patient is in a lucky position to be in the hospital where a treatment could be given under direct supervision. Was that done?Dr Currie: We can give you the answer to that shortly.Professor Garry Jennings: I just take issue with the last point of Professor Delles that there is target organ damage in this lady. She has 40 pack years of tobacco smoking behind her. She has hypercholesterolemia. She has high cardiovascular risk anyway and you would almost be surprised if she didn’t have atherosclerosis irrespective of what her blood pressure was.Professor Delles: Yes. We will show something on her carotid ultrasound in a bit. I think it would be interesting to find out what the audience thinks because we do see patients who definitely have high blood pressure but relatively little organ damage. Let’s not discuss it with this patient specifically, but we have patients where we think it is kind of the wrong way around and we do not understand the mechanism very well.Professor Touyz: Professor Delles brings up a really important point. We see increasingly in our clinics patients with confirmed very high blood pressure based on ambulatory readings, and yet absolutely normal renal function, no evidence of LVH, no ischemic heart disease. We don’t really understand what is happening and we often question whether there might be a differential between central blood pressure and peripheral blood pressure. Perhaps this is something we may be able to discuss later as we progress this case.Professor Staessen: You also asked which drug we would not prescribe to this patient. I think this lady is extremely vulnerable to heart failure because she has previous MI. She has coronary heart disease even if she doesn’t have LVH. Because of her blood pressure level, she is prone to develop heart failure. Now if you look at the trials of moxonidine, there is an increased mortality in patients with heart failure. That drug I would certainly not have prescribed to this patient, although it is very popular among cardiologists.Professor Delles: Thank you very much for confirming this. This was the only drug that I mentioned in some of the clinic letters specifically and said this is the one I don’t want her to take for exactly the reasons that you said.Audience participant: It is amazing not to have more pronounced albuminuria and “just” to have heart disease. It’s not just about organ damage because maybe she would also have atherosclerotic disease, so there are very stiff arteries. I think this is something we have in mind for this patient.Professor Delles: You are prompting us in a wonderful way.We Learn More…Between 2010 and 2012, the patient continued to attend the blood pressure clinic on a regular basis. Body mass index was relatively normal, ≈26 kg/m2, but some dietary changes in terms of calorie and salt restriction were made resulting in a 3-kg reduction in weight over a 6-month period. The antihypertensive regime was adjusted: furosemide dose was increased, ramipril was doubled, α-blockade was doubled, and spironolactone was added at a dose of 25 mg once daily. Again, this patient is attending many clinics, seeing cardiologists, vascular surgeons, and the blood pressure service. It does not seem that all of these changes were made by the staff at the blood pressure clinic.Parallel to this, ischemic heart disease continued to be problematic, and a further non–ST-segment–elevation MI occurred toward the end of 2010 requiring another percutaneous procedure. Ivabradine was then commenced for control of angina.The first ambulatory blood pressure monitor for this patient in 2011 had a suboptimal number of readings. Nevertheless, it confirmed that overall blood pressure was 155/90 mm Hg but with quite a degree of variation in readings. The minimum blood pressure was 119/56 mm Hg and maximum 203/119 mm Hg.The audience raised many discussion points; the first of which was the issue of compliance. During this patient’s week on the ward, the antihypertensives were administered by nursing staff, and 12-hour daytime average blood pressure during admission was 144/86 mm Hg.The next interesting point is a note in a clinic letter following one of several percutaneous coronary interventions. It states that the invasively monitored central blood pressure was significantly less than the peripheral reading. Systolic blood pressure during the procedure ranged between 83 and 130 mm Hg and diastolic blood pressure between 45 and 55 mm Hg. This raises the question of whether the peripheral blood pressure readings are falsely high because of increased vascular stiffness.Adherence and Vascular StiffnessProfessor Delles: Two points we would like to discuss are adherence and vascular stiffness leading to probably falsely high peripheral pressures.We have data for patients who were worked up for renal denervation, which we will discuss later during the case.5 One should assume that these patients were fully investigated before admission for an invasive procedure. But if you look at these data, treatment adjustment normalized blood pressure in almost half of these patients. There were many other considerations, such as nonexcluded secondary hypertension and other factors that may account for apparent treatment resistant hypertension.We think that we at least adjusted drug treatment, whether it was in the optimal way is still open for discussion. We are fairly sure that we have not missed too many reasons for secondary hypertension. However, poor drug adherence is still quite a significant contributor to resistant hypertension.Also to prompt the discussion, we now have methods for drug metabolite monitoring available. Would this really play a role in patient management? Very briefly, what these data from Tomaszewski et al6 in Leicester show is that people who have no discrepancy (near 0) between the number of drugs prescribed and the number of drugs found in their urine as metabolites have much lower blood pressure than people with discrepancy of ≤6. That accounts for all clinic and ambulatory blood pressure measurement. Do these new methods have a role in clinical practice or is it more useful as a research tool for very specific cases? How do we actually handle such information? If we obtain it, how do we inform the patients that we do these measurements?The other issue mentioned by Dr Currie is that the patient may have increased vascular stiffness, which could certainly lead to a high peripheral blood pressure, whereas the central blood pressure may be much lower.The patient recently attended our noninvasive vascular phenotyping clinic in the clinical research facility for vascular functional and structural studies. The carotid intima-media thickness is slightly increased at 1.6 mm that is higher than expected for her age. She does not have significant carotid stenosis, but images showed a small plaque. This confirms some organ damage, at least atherosclerotic disease.Pulse wave velocity was also measured using the new SphygmoCor system that uses oscillometric assessment. Measurement was performed repeatedly, and we present the best tracing obtained. It shows a pulse wave velocity of 11.4 m/s that is not extremely high. It would actually be in the normal range for someone at that age. At the time of investigation, peripheral blood pressure was 152/88 mm Hg and central estimated/calculated blood pressure was 145/89 mm Hg. There is not a large discrepancy.What is the relevance of central blood pressure if it can be reliably measured? There are reference values now available for central blood pressure, published last year by Annie Herbert in the European Heart Journal,7 but would this really influence treatment? Would we be brave enough to target our treatment to central blood pressure? In one of the recent issues of Artery Research, there was a very nice discussion about whether we should use central blood pressure in the clinic.8,9There are some data from the Conduit Artery Functional Endpoint (CAFE) study showing that blood pressure medication affects central and peripheral blood pressure differently; specifically, it was very clear that amlodipine-based therapy lowered both central and peripheral blood pressure, whereas the β-blocker atenolol lowered only the peripheral blood pressure.10Professor Staessen: I would like to make a comment on the last slide you showed from the CAFE study. I think when you look at the Table of this article, there is absolutely no difference in predictive value of peripheral and central pulse pressure. I think that looking at central pressure will not, at least at this stage of scientific development, help in managing treatment of hypertensive patients. I think measuring central pressure is a nice tool for research but not for clinical practice.And then the other thing is I noticed there was a very big difference between systolic and diastolic pressures. Now you have the heart rate relatively high, so did you look at the aortic valve? I also noticed that if you look at the tracing of the artery, there is no incisura, so no sign of closure of the aortic valve and she has calcification. Is there calcification of the aortic valve? Is there aortic insufficiency? This might explain the big difference between systolic and diastolic pressures.Dr Currie: Your point with the central blood pressure reading is well taken and I think that was the point we were trying to make. Although these tools are available and we have reference ranges for them, we still don’t really know how to use them or interpret them in the clinical context. I don’t think anyone would in their clinical day to day practice rely on a central rather than a peripheral blood pressure reading.Her aortic valve was normal in echocardiogram on admission to the investigation unit, but I should raise the point that these vascular studies were only done last week and there has not been a repeat echo in the recent past. Therefore, we cannot be sure whether there has been a change and her valve has become more calcified.Professor Delles: We had discussions as well in recent sessions at this meeting about the workup of patients with resistant hypertension and workup of patients with secondary hypertension. I think one of the messages that was very, very clear is that we should not just do our investigations at a single time point. Generally, clinicians are reluctant to do too many echocardiograms in “normal” hypertensive patients because there is not much to gain from this, but in this patient with resistant hypertension, we should definitely have performed another echo more recently.Professor Touyz: I think Professor Dominiczak and I both have questions regarding her treatment. I just want to go back to the therapy. She is now on 3 diuretics, is this correct?Professor Delles: That is correct.Professor Touyz: Why is she still on 3 diuretics and does she have any evidence of heart failure, and if not, why is she still on furosemide?Delles: Well spotted. If we want to criticize something in the management, then it is probably this: there were multiple teams involved. The cardiologists were reasonably keen on the furosemide for reasons that I do not fully understand. It was also a subjective factor that the patient required the furosemide to some extent. As mentioned by Professor Staessen, this combination of the thiazide and the loop diuretic to start with was probably not a very rational idea. Then to add the spironolactone because we think we have some evidence, but not realizing that this adds a third diuretic was probably not the cleverest step. I cannot 100% defend this.Professor Dominiczak: Could I come back to the drug screen measuring metabolites in the urine? Having heard and seen presentations at this meeting and read the previous paper that you referred to, this is really a cheap and good way to check adherence and compliance. I think we don’t use it enough, and one message for me from this case is that it would have been much easier to do a drug screen earlier even if you need to send the urine somewhere and make sure that it is done properly. In another room, just an hour ago, we were talking about measuring thousands of metabolites for research. Why can’t we measure 6 drug metabolites that are well known to toxicologists in the urine of our patients? It seems rational, easy, and I think a patient confronted with the result where there is zero drug level might start taking tablets. It is not just for your knowledge, but it is for the benefit of the patient who might become compliant being confronted with the truth.Professor Touyz: You bring up a really interesting point there because the question then arises why is the patient not taking the medication and exactly how do you confront the patient? I think there is some evidence that confronting patients in such a way actually pushes them away even further and they do not come back to the clinic for follow-up. We have something quite interesting with respect to behavioral changes and how one as a clinician and healthcare provider deals with these very complex psychological factors that we haven’t really thought about in the past.Dr Melvin D. Lobo: Coming back to the idea of which drugs you may or may not give somebody with uncontrolled hypertension, I would take issue with what has been said so far. I would say that if you prove extremely refractory hypertension, there are no holds barred on any drug that you might prescribe to get blood pressure down. Because in the face of an unremitting afterload, your options are actually dictated by getting the afterload down. You can worry about various studies that don’t incorporate this kind of patient or you can just get on and sort out the blood pressure.Now, is this woman actually hypertensive? I haven’t heard any discussion of why the blood pressure is normal in the cardiac catheterization lab, which is the greatest stimulus to hypertension man knows. We frequently have patients sent back from cardiac catheterization because they are so nervous about the procedure. Why isn’t intra-arterial monitoring giving us these blood pressures?Then observed tablet taking in hospital, how well was it done? Did you actually check her mouth afterward to ensure the tablets had been ingested?Professor Delles: The blood pressure in the cardiac catheterization laboratory was probably the feature that was really striking for us. She should have been a little bit more hypertensive there, but again it is unknown exactly how sedated the patient was at that time so that may have contributed.As you know, cardiologists do not assess blood pressure very precisely during these procedures. If this was really measured in parallel or if at some point, they had a central pressure that was lower but did not have the corresponding peripheral blood pressure at exactly the same time, it is difficult to say.Dr Currie: With regard to observed medication taking, this is something that our inpatient nurses do regularly. I would be fairly convinced that they check the patient has ingested the medication and would be quite alert to observing any behavior that might suggest it was not ingested. Although the 12-hour daytime blood pressure during inpatient stay was significantly lower, I think if the patient wasn’t taking all of those 7 antihypertensive agents and then suddenly took them all as an inpatient, would we not expect it to be even lower? Would she be symptomatically hypotensive?Professor Jennings: I want to talk about the issue of drug metabolites which I think are the thing of the future. I think they are very, very useful and we certainly do it. However, we’ve already encountered a well-known form of nonadherence. That is people would take the drugs just before they go

Abstract:HomeHypertensionVol. 74, No. 5Paroxysmal Hypertension Associated With Urination Free AccessIn BriefPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessIn BriefPDF/EPUBParoxysmal Hypertension Associated With Urination Ying Lou, Luyun Fan, Xiaopei Hou, Anna F. Dominiczak, Ji-Guang Wang, Jan A. Staessen, Bader Almustafa, SiewMooi Ching, Alexandre Persu, Michael Bursztyn, Jun Cai and Huimin Zhang Ying LouYing Lou From the Department of Hypertension, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.L., L.F., J.C., H.Z.) *These authors contributed equally to this work. Search for more papers by this author , Luyun FanLuyun Fan From the Department of Hypertension, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.L., L.F., J.C., H.Z.) *These authors contributed equally to this work. Search for more papers by this author , Xiaopei HouXiaopei Hou Department of Geriatrics and Gerontology, Beijing Friendship Hospital, Capital Medical University, Beijing, China (X.H.) *These authors contributed equally to this work. Search for more papers by this author , Anna F. DominiczakAnna F. Dominiczak Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (A.F.D.) Search for more papers by this author , Ji-Guang WangJi-Guang Wang Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluation, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China (J.-G.W.) Search for more papers by this author , Jan A. StaessenJan A. Staessen Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (J.A.S.) Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands (J.A.S.) Search for more papers by this author , Bader AlmustafaBader Almustafa Qatif Hypertension & Cardiometabolic Unit, Qatif Primary Health Care Center, Saudi Arabia (B.A.) Search for more papers by this author , SiewMooi ChingSiewMooi Ching Department of Family Medicine, Faculty of Medicine and Health Science, Universiti Putra Malaysia, Selangor, Malaysia (S.M.C.) Search for more papers by this author , Alexandre PersuAlexandre Persu Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium (A.P.) Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium (A.P.) Search for more papers by this author , Michael BursztynMichael Bursztyn Department of Medicine, Hypertension Unit, Hadassa-Hebrew University Medical Center, Mount-Scopus, Jerusalem, Isreal (M.B.). Search for more papers by this author , Jun CaiJun Cai Jun Cai, Department of Hypertension, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167, Beilishi Rd, Xichen District, Beijing 100037, China, Email E-mail Address: [email protected] From the Department of Hypertension, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.L., L.F., J.C., H.Z.) Search for more papers by this author and Huimin ZhangHuimin Zhang Correspondence to Huimin Zhang, Department of Hypertension, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167, Beilishi Rd, Xichen District, Beijing 100037, China, Email E-mail Address: [email protected] From the Department of Hypertension, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.L., L.F., J.C., H.Z.) Search for more papers by this author Originally published30 Sep 2019https://doi.org/10.1161/HYPERTENSIONAHA.119.13140Hypertension. 2019;74:1068–1074Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: September 30, 2019: Ahead of Print Case IntroductionTwo cases were hospitalized in our hospital at the same period. Case 1 was a 40-year-old woman who presented with a 2-year history of episodes of high blood pressure associated with severe headache, pallor in appearance, and cold sweating. The high blood pressure episodes occurred within 1 to 2 minutes after urination, at which time her blood pressure shot up to 180/120 mm Hg. They only lasted for a few minutes and then relieved spontaneously. However, she complained of a 1-month history of aggressive symptoms before admission. Her father had a history of hypertension. On physical examination, her blood pressure was 130/80 mm Hg, with a heart rate of 70 bpm. Other systemic examinations were normal. The urinalysis, electrocardiography and echocardiography tests were normal.Case 2 was a 50-year-old man with a 10-year history of episodic hypertension, and his symptoms also appeared 1 to 2 minutes after urination, especially after the first-morning urine. His blood pressure was slightly higher than case 1 at 200–250/100–120 mm Hg, and his symptoms lasted for a few seconds to 5 minutes. However, strikingly, he was very nervous and scared of urination. In terms of physical examination, we found that he was slightly overweight with a blood pressure of 146/68 mm Hg. Echocardiography examination revealed a thickened interventricular septum of 13 mm and left ventricular diastolic dysfunction.In summary, our patients both had remarkable postmicturition symptoms, including paroxysmal hypertension, severe headache, palpitation, and sweating. However, their symptoms only lasted a few minutes and recovered spontaneously. What possible diagnoses and further examinations would you suggest?Discussion: Further ExaminationsProfessor Staessen: I would probably do a bladder endoscopy and echography of the lower urinary tract.Dr Almustafa: From the presentation, being a primary care physician and a clinical hypertension specialist, I would say it seems that I am facing a case of pheochromocytoma-like symptoms. Let me go further. Are there any complications? Anything else? I may give the patient a monitor for ambulatory blood pressure to take home if the office blood pressure is not that high, just to give me more clarification about this pheochromocytoma. In addition, I would definitely go for a fundus to look for any, what seems to be, masked hypertension. I may see some findings, some early changes of hypertensive fundus changes. In addition, I may go further than the ambulatory blood pressure and fundus examination. I have not heard anything about the electrocardiography findings, which could make it simple for a primary care physician to be suspicious earlier.Professor Dominiczak: Could I revisit Professor Staessen’s suggestion? With these symptoms, I would be very careful to proceed to cystoscopy since we know that, if our second speaker is right, any anesthesia, procedure or pressing on the source of excessive catecholamines in such a patient could really cause a storm and a very severe situation. So, I would want to first measure things in the laboratory before I proceed to any procedure at all because I have seen tragedy with patients like that.Associate Professor Staessen: I agree.Dr Ching: I am also a specialist, so I totally agree with Professor Dominiczak’s suggestion. In addition to assessing for secondary organ damage, I would also like to confirm the diagnosis. Of course, because episodic hypertension together with severe headaches and the adrenergic response suggests pheochromocytoma, I would order 24-hour urinary catecholamines. I would also assess renal function and urinary albumin to assess for secondary organ damage. Since we want to confirm the diagnosis on top of ruling out that this is resistant hypertension, we have to look for secondary organ damage and confirm the diagnosis.Professor Dominiczak: Okay, so we have similar comments. Any other additional comments that do not confirm the same?Professor Staessen: One way or another, one has to document increased excretion of catecholamines from 24-hour urinary collections.Professor Dominiczak: In our center, we would collect 24-hour urinary excretion of every catecholamine we can measure and that would give us a first indication. With this presentation, they would be sky-high, I think.Biochemical TestsAccording to typical symptomatic indications, we suspected the diagnosis of pheochromocytoma or paraganglioma (PPGLs) in these cases. We performed plasma catecholamine examinations 4 times upon symptom attack in case 1. In the latter 2 examinations, we observed slight elevations of norepinephrine and epinephrine. Also, we performed plasma-free metanephrine examinations, but nothing interesting was observed. Nevertheless, the 24-hour urinary fractionated metanephrine examination revealed slightly elevated normetanephrine (Table).Table. Biochemical Testing Results of CasesBiochemical TestsCase OneCase TwoPlasma catecholamines (symptoms attack 1) Norepinephrine (normal, 0.104–0.548 ng/mL)0.2331.524 Epinephrine (normal, 0.02–0.08 ng/mL)<0.0050.165 Dopamine (normal, <0.03 ng/mL)<0.0050.027Plasma catecholamines (symptoms attack 2) Norepinephrine (normal, 0.104–0.548 ng/mL)0.5312.149 Epinephrine (normal, 0.02–0.08 ng/mL)<0.0050.136 Dopamine (normal, <0.03 ng/mL)<0.0050.023Plasma catecholamines (symptoms attack 3) Norepinephrine (normal, 0.104–0.548 ng/mL)0.6721.434 Epinephrine (normal, 0.02–0.08 ng/mL)0.1020.096 Dopamine (normal, <0.03 ng/mL)<0.005<0.005Plasma catecholamines (symptoms attack 4) Norepinephrine (normal, 0.104–0.548 ng/mL)0.6482.554 Epinephrine (normal, 0.02–0.08 ng/mL)0.0950.397 Dopamine (normal, <0.03 ng/mL)<0.0050.025Plasma-free metanephrines (supine) 3-methoxytyramine (normal <28 pg/mL)4.07812.251 Normetanephrine (normal <163 pg/mL)69.251994.648 Metanephrine (normal <96.6 pg/mL)14.66527.82724 h urinary fractionated metanephrines Normetanephrine (normal:1–1464 µg/24 h)15678447 Metanephrine (normal: 0–394 µg/24 h)111454In case 2, during the 4 examinations, we found remarkably elevated norepinephrine and epinephrine. We also found around 4- to 7-fold elevation of plasma-free normetanephrine. Additionally, the 24-hour urinary fractionated metanephrine examination revealed dramatically elevated normetanephrine and nearly 1.5-fold elevated metanephrine (Table).Since biochemical tests of PPGLs were positive, what next step would you suggest? As we all know, the pheochromocytomas are derived from the adrenal gland, and the paragangliomas are derived from extra-adrenal chromaffin cells.1,2 What would you suggest to find the tumor?Discussion: Finding the TumorDr Almustafa: I guess once the biochemical tests of PPGLs are positive, I would go for a computed tomography (CT) of the abdomen to clarify whether there is something, before performing further examination. Maybe the CT would be the next step I would do.Professor Dominiczak: So, what is your first test?Dr Almustafa: I would go for a CT of the abdomen.Professor Dominiczak: CT of the abdomen?Dr Qi: I think the symptoms were induced by micturition. So, I think the bladder should be checked first. I think the first test should be ultrasonography, then CT, and finally, maybe, endoscopy.Associate Professor Ching: We should consider noninvasive and invasive ways of testing. So, noninvasively, we of course have to make sure that these manifestations are really related to urination. I would like to measure blood pressure before and after urination. And after that, of course, a CT of the abdomen would be first because I think that in the presentation, the ultrasound was normal. So, I think a CT of the abdomen would be my first line. But, of course, from there, I could identify the location and then decide later whether I want to perform the invasive tests.Professor Persu: I agree with the CT angiography proposal, but in parallel, or immediately after, I would go for some sort of scintigraphy, such as metaiodobenzylguanidine scintigraphy. This is because first, it could be a very small tumor that is difficult to detect by CT, and second, it would allow for detection of additional associated paraganglioma elsewhere, maybe.Ultrasound ResultsSince the symptoms were related to micturition, we thought the tumor could be close to the urinary bladder. We chose ultrasound first because this is the easiest and most economical modality. For case 1, the result of the abdominal and pelvic ultrasound was negative. But, in case 2, we found a 35×20 mm-sized mass located in the anterior part of the urinary bladder.For case 1, we had to ask ourselves: are we in the correct direction of diagnosis? Case 1 was a middle-aged female patient with episodic hypertension, palpitation, headache, and sweating, but only slightly elevated metanephrines levels were observed. Furthermore, pelvic ultrasound was normal. Is it possible that this patient just has some kind of psychosomatic disorder, such as anxiety or panic attacks, which can be common in middle-aged female patients?Discussion: Directions for DiagnosisDr Almustafa: Ambulatory blood pressure would clarify the issue, and I cannot really imagine that a panic attack may account for such dramatic symptoms after micturition. And, if it is so, it means that I am dealing with a urologic problem that I need to solve very urgently, which will also necessitate a CT of the abdomen and pelvis. I do agree with ultrasound to begin with, but this will not answer the issue. Ultrasound has to be done just for a quick answer, but it will not tell me whether to do CT or not. I am going to do CT, whatever the results of the ultrasound.Dr Bursztyn: I have a comment about the slightly elevated metanephrine. When testing for catecholamines and metanephrines, preanalytical procedures are of extreme importance. Was the patient sitting or lying down? Was the temperature cold, or was it pleasant? Was it a noisy place? Catecholamines and metanephrines are quite sensitive to preanalytical procedures, which unfortunately is sometimes forgotten.Professor Dominiczak: Another consideration is drug treatment and whether the patient is on any drug treatment that could interfere with the measurements.Dr Li: I agree with the presenting doctors that it is possible this female patient had a panic attack. However, even if the ultrasound examination is negative, we still need more accurate imaging to exclude the possibility of pheochromocytoma.Images of CT scansWe performed CT scans in these 2 patients (Figure 1) according to the recommendation that CT, rather than magnetic resonance imaging, is the first-choice imaging study for thorax, abdomen, and pelvic PPGLs from the Guidelines.3,4 The adrenal CT scan revealed nothing special. But, in case 1, the pelvic CT scan disclosed an 8.2×10.5 mm mass located in the right back wall of the bladder, with an increase in density after iodine injection.Download figureDownload PowerPointFigure 1. Images of Computed tomography(CT) scans. Negative adrenal computed tomography (CT) scan in case 1 (A); pelvic CT scan in case 1 revealed an 8.2×10.5 mm mass located in the right back wall of bladder (B); negative adrenal CT scan in case 2 (C); pelvic CT scan in case 2 revealed a 35×27 mm mass located in the anterior wall of bladder, with a heterogeneous increase in density after iodine contrast injection (D).Similarly, in case 2, pelvic CT showed a large mass located at the anterior wall of the bladder.Finally, the CT scan helped us find the tumor in the female patient. The extremely small size and hidden location of the tumor might explain why we could not find it easily. The next question is is that enough for these 2 patients? What kind of other examination do you think they should undergo next?Discussion: Next StepsProfessor Persu: Now it is time to perform scintigraphy—for example, MIBG scintigraphy—to confirm the diagnosis but also to be sure there are no additional lesions.Functional Imaging ExaminationsFunctional imaging examinations are very important for the diagnosis of PPGLs, are complementary to anatomic imaging, and provide functional characterization of tumors. Also, functional imaging examination is a whole-body exploration and is particularly useful for the evaluation of multifocality or for detection of metastatic disease. Functional imaging examinations include MIBG, octreotide scintigraphy, and positron emission tomography.4–6We performed octreotide scintigraphy and iodine-131-MIBG scintigraphy (Figure 2) and found no focal area of increased tracer uptake in the whole-body survey of case 1. But, in case 2, we found an increased 131I-MIBG uptake of the 27×30-mm sized mass in the anterior wall of the bladder.Download figureDownload PowerPointFigure 2. Functional Imaging Examination. Negative 99 m Tc-octreotide scintigraphy in case 1 (A); negative 131I –MIBG scintigraphy in case 1 (B); negative 99 m Tc-octreotide scintigraphy in case 2 (C); 131I –MIBG scintigraphy in case 2 revealed an increased uptake in a 27×30 mm size mass at the anterior wall of bladder (D). L indicates left; and R, right.Why is the octreotide scintigraphy negative in both patients?Discussion: Diagnostic Accuracy of ScintigraphyProfessor Persu: I think octreotide scintigraphy performs better in the nonsecreting head and neck paraganglioma, while MIBG is more for adrenal or, maybe, extra-adrenal pheochromocytoma with catecholamine secretion. However, you had to perform both because it may vary from case to case.Dr Lou: As we all know, octreotide scintigraphy is a somatostatin receptor scintigraphy, and somatostatin receptors are expressed in many kinds of neuroendocrine tumors. The sensitivity of the octreotide scintigraphy is highly body-region dependent. A previous study analyzed SDHx gene-related PPGLs in patients, finding the highest octreotide sensitivity in head and neck paragangliomas and the lowest sensitivity in abdomen paragangliomas and pheochromocytomas.7 Given the limited study population, determining the sensitivity and specificity of octreotide scintigraphy requires more large-scale clinical studies. The next question is how to explain the difference of the MIBG results in these 2 patients.Dr Bursztyn: Usually, there is quite good correlation between the level of secretory potential of the tumor and its uptake. So, I think in case 1, the minimally elevated catecholamines and the small size of the tumor would be the causes, if it was negative.Dr Lou: For case 1, a smaller tumor always leads to less function, so it may lead to a false-negative in MIBG scintigraphy. Also, the sensitivity of MIBG scintigraphy ranges from 56% to 75% for paragangliomas, which means almost one-third of patients are MIBG-negative.4Case Resolution and PrognosisThe diagnosis of these 2 patients is urinary bladder paraganglioma and the therapeutic strategy is surgery after appropriate medical preparation.Case 1 underwent transurethral resection of the bladder tumor after orally taking an alpha-blocker, phentolamine, for 4 weeks. We also performed postoperative histological examination (Figure 3), and we found that the tumor tissue was composed of spindle-shaped, slightly metatypical cells and was positive for chromogranin. The immunohistochemical results (CgA[+], Syn[+], CD56[+], S-100[+], and Ki-67[<5%+]) also confirmed the diagnosis of bladder paraganglioma.Download figureDownload PowerPointFigure 3. Postoperative Histological Examinations. Histological examination in case 1 depicted spindle-shaped slight metatypical cells (A, hematoxylin and eosin [H&E], ×10) and positive chromogranin (B, immunohistochemical, H&E,×40); histological examination in case 2 presented typical Zellballen growth pattern of paraganglioma (C, H&E, ×40) and neoplastic cells composed of round or epithelioid cells with acidophilic cytoplasm and vacuolated nucleus (D, H&E, ×10); excised tumor from case 2 (E).Case 2 also experienced resection of the bladder tumor and partial bladder resection after taking alpha-blockers orally for 4 weeks. The typical Zellballen growth pattern of the tumor cells was observed in the postoperative histological examination, as well as positive immunohistochemical results (CgA[+], Syn[+], CD56[+], S-100[+], and Ki-67[<5%+]), which were consistent with the diagnosis of bladder paraganglioma (Figure 3).We followed up these 2 patients for 2 years, and no paroxysmal hypertensive symptoms reappeared.Now it seems to be a story with a happy ending, but genetic testing should not be forgotten as it is strongly recommended by current guidelines.3,4 We performed genetic testing only in case 2 as it was refused by case 1 The peripheral blood test showed no germinal mutation of PPGL-related genes, including RET, NF, VHL, SDHB, and other related genes.4,8 But, for the tumor tissue test, we found a RET gene 341 site G to A mutation. Can we state that there is no germline mutation, but a somatic mutation exists? What do you think of the genetic test results?Discussion: Genetic TestsProfessor Persu: First, I agree it was important to look for a germinal mutation in SDHB because it is associated with an increased risk of malignancy. But still, in some cases, you may identify an SDHD or even SDHC mutation. Did you look for mutations in these genes?Dr Lou: Yes, all the SDHx series genes were screened.Professor Persu: Then, my second question is about the somatic mutation. Was this mutation already described in the past as a germinal mutation?Dr Wang: Was this a new mutation or one already reported previously?Dr Lou: It is not a new mutation. It has been reported.3,9Professor Persu: Was it associated with a syndromic form of pheochromocytoma in the literature as a germinal mutation?Dr Lou: Yes.10Professor Persu: Thank you. This is interesting. Nevertheless, I would like to provide a reminder that the current recommendation is to screen for germinal mutations in patients with PPGL. Searching for somatic mutations is, in principle, reserved for research, and in the present case, I do not think identification of a somatic RET mutation will change the follow-up.Professor Dominiczak: Have you inquired more as to why case 1 refused genetic testing? People normally want to know. Was there something in her family history that made her afraid of genetic testing? Maybe there was a similar case; maybe she remembered something about her parents? Have you tried to understand this refusal?Dr Lou: In our hospital, we have a commercial panel for hypertension-related genes.Professor Dominiczak: That is an easy explanation. I come from a country where every test is free at the point of delivery, so I would not understand.Dr Wang: Well, actually, in China, we also have the same problems you have. Some family members are afraid of this kind of testing because they just do not like it. Recently, we had a Gitelman syndrome family, but the family members refused to provide blood for genetic testing because they do not have any symptoms. They said they would not do any genetic testing for that. The same thing happens in China. Even if we provide free testing, they may still refuse.Overview of Urinary Bladder ParagangliomasUrinary bladder paraganglioma is very rare, as it represents around 9.8% of all extra-adrenal paragangliomas and only 0.06% of all primary urinary bladder tumors.2,11 Typical manifestations of urinary bladder paragangliomas include hematuria, hypertension, headache, sweating, and tachycardia or palpitation, provoked by micturition or overdistension of the bladder.12,13 Remarkably, early diagnosis of urinary bladder paraganglioma is necessary because delayed diagnosis can lead to target organ damage involving heart, kidney, brain, and the fundus of eyes. For instance, severe morbidities such as hypertensive crisis and catecholamine cardiomyopathy can occur due to undiagnosed and uncontrolled paragangliomas. Most importantly, after the correct diagnosis and surgery, hypertension secondary to paraganglioma is curable in nearly all patients.12,13How do we diagnose urinary bladder paraganglioma? We need biochemical tests including plasma and urine metanephrines; imaging studies including ultrasound examination, CT scan, and magnetic resonance imaging; and functional imaging studies including MIBG scintigraphy, positron emission tomography, and octreotide scintigraphy.4In terms of treatment, all patients with urinary bladder paragangliomas should undergo surgery as soon as possible. However, preoperative medical management, including prescription of alpha-blockers for at least 7 to 14 days before surgery, is very important for blockading alpha-receptors. Beta-blockers should only be added to control tachycardia after the administration of alpha-blockers. Also, a high-sodium diet and fluid intake should not be forgotten to prevent hypotension during operation. Surgical strategies include transurethral resection or open resection, depending on the location and size of the tumors.4,9Regarding prognosis and follow-up, urinary bladder paragangliomas are usually benign, so the prognosis is usually good.14–16 Unfortunately, there are no specific pathological criteria for predicting malignancy, and reliable indicators of malignancy are limited to invasion of adjacent tissue or metastatic spreading.17 Long-term follow-up is needed to investigate reoccurrence.In conclusion, urinary bladder paraganglioma is rare and challenging to identify because of the various clinical, imaging, and pathological appearances. Early recognition, diagnosis, and treatment result in improved outcomes. Long-term follow-up is needed.Final DiscussionDr Almustafa: What was the early presentation of these 2 cases to the health facility? How did they present? You are presenting final symptoms. I need a record of early symptom presentation investigation. It is not all of a sudden that they developed such symptoms.Dr Wang: It is better to tell us what happened before they were admitted into your care.Professor Dominiczak: Before they were with their primary care physician, what was their first presentation?Dr Fan: They had visited other hospitals before but had no diagnosis. So, they were finally transferred to our clinic. After we took the history of their symptoms, we thought there might be a suspicion of PPGLs.Dr Wang: And why did they originally go to the doctor?Dr Fan: Because they were scared of urination. After urination, they were scared of the paroxysmal hypertension, headaches, and severe palpitations, so they came to the hospital.Dr Almustafa: How did they know that they had high blood pressure?Dr Wang: Yes, how did they identify high blood pressure after they urinated?Dr Fan: Because they had headache and palpitation symptoms associated with hypertension.Associate Professor Ching: In your slide, you mentioned that typical presentation would be hematuria. In this patient, I think this symptom was not present. Would you like to give some information from the literature? How many of them actually have absence of hematuria? Because in the presence of hematuria, I think the diagnosis is very easy.Dr Fan: The literature about bladder paraganglioma is very scarce. We searched and found 2 studies about this condition. Only nearly 50% of patients have very typical postmicturition symptoms. The other 50% might just have a headache or hypertension.12,15Associate Professor Ching: I feel that it is not a typical presentation; rather, it is an atypical presentation of the paraganglioma of the bladder.Professor Dominiczak: You said that you frequently administer alpha-blockers first and when the patient is completely alpha-blocked, you then add beta-blocker, which is the standard. You did not do it in these cases. If I understand correctly, you stayed with alpha-blockers alone for both cases. Why?Dr Fan: Our first choice is alpha-blockers. Only when the patients have tachycardia, do we use beta-blockers.Professor Dominiczak: Only with tachycardia?Dr Fan: Yes, with tachycardia. The first choice is alpha-blockers for catecholamine crisis after surgery.Professor Dominiczak: The belief in some centers is that you block everything you can block. The ambition in our center has always been that the physician goes to the operating theater, and whether it is cystoscopy or open surgery, the blood pressure should not move an iota during surgery, meaning you blocked properly.Dr Bursztyn: Absence of tachycardia suggests that there was not enough alpha-blockade.Professor Dominiczak: Precisely.Dr Wang: Actually, in China, the current practice is that you start with an alpha-blockade. If there is, as Dr Fan said, tachycardia, then we use beta-blockers. Otherwise, we do not. That is the current practice. We would probably consider a trial comparing surgery with or without beta-blockers. For instance, in the absence of tachycardia, it could determine whether beta-blockade would help clinical outcomes of an operation.Professor Dominiczak: I think the patient is more stable if everything is blocked. Alpha first, then add beta. Then you have everything blocked, and the patient is stable during the procedure.SummaryWe herein reported 2 rare cases of urinary bladder paraganglioma presenting with severe postmicturition syndrome and paroxysmal hypertension, in the absence of hematuria. Biochemical tests of plasma catecholamines after symptoms’ onset and determinations of metanephrines in plasma or urine can assist in screening for paragangliomas but can also be falsely negative due to multiple factors such as small tumor size, preanalytical procedures, and concomitant medications. Imaging tests are required to identify the location and size of the tumor, with thorax, abdomen, and pelvis CT scans recommended. Functional imaging examinations including MIBG, octreotide scintigraphy, and positron emission tomography are needed to identify additional lesions and their function via whole-body exploration. Diagnostic accuracy of different functional imaging examinations highly depends on the type and location of tumors and requires further investigation. Genetic tests are valuable for prediction of increased risk of malignancy in affected individuals and their relatives. Surgery after sufficient adrenergic blockage remains the mainstream treatment for localized tumors with generally optimistic outcomes. Long-term follow-up is necessary to monitor tumor recurrence.AcknowledgmentsWe are grateful to the following session audience members for contributing to the discussion: Lixing Qi and Yan Li.Sources of FundingThis work was supported by Peking Union Medical College Youth Fund (Project ID. 2017320009, from Y. L.), the CAMS Innovation Fund for Medical Sciences (CIFMS,Project ID. 2016-12M1–006, from J. C.), and the National Natural Science Foundation of China (Project ID. 81630014, 81825002, 81470541, 81870318, 81670379, from Prof J. C. and Project ID. 81770504, from H. Z.).DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.*These authors contributed equally to this work.The following case was presented on 26 September 2018 as part of the Clinical-Pathological conference chaired by Anna F. Dominiczak and Ji-Guang Wang at the 27th Scientific Meeting of the International Society of Hypertension. Luyun Fan and Ying Lou presented the case and led the discussion.Correspondence to Huimin Zhang, Department of Hypertension, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167, Beilishi Rd, Xichen District, Beijing 100037, China, Email [email protected]comJun Cai, Department of Hypertension, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.167, Beilishi Rd, Xichen District, Beijing 100037, China, Email [email protected]orgReferences1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma.Lancet. 2005; 366:665–675. doi: 10.1016/S0140-6736(05)67139-5CrossrefMedlineGoogle Scholar2. Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma.J Urol. 1992; 147:1–10. doi: 10.1016/s0022-5347(17)37119-7CrossrefMedlineGoogle Scholar3. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS; International Symposium on Pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005.Nat Clin Pract Endocrinol Metab. 2007; 3:92–102. doi: 10.1038/ncpendmet0396CrossrefMedlineGoogle Scholar4. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.J Clin Endocrinol Metab. 2014; 99:1915–1942. doi: 10.1210/jc.2014-1498CrossrefMedlineGoogle Scholar5. Chen L, Li F, Zhuang H, Jing H, Du Y, Zeng Z. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.J Nucl Med. 2009; 50:397–400. doi: 10.2967/jnumed.108.058693CrossrefMedlineGoogle Scholar6. Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, Jacobson AF. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.J Nucl Med. 2009; 50:1448–1454. doi: 10.2967/jnumed.108.058701CrossrefMedlineGoogle Scholar7. Michałowska I, Ćwikła JB, Pęczkowska M, et al. Usefulness of somatostatin receptor scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-metaiodobenzylguanidine scintigraphy in patients with SDHx gene-related pheochromocytomas and paragangliomas detected by computed tomography.Neuroendocrinology. 2015; 101:321–330. doi: 10.1159/000381458CrossrefMedlineGoogle Scholar8. Neumann HP, Bausch B, McWhinney SR, et al; Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma.N Engl J Med. 2002; 346:1459–1466. doi: 10.1056/NEJMoa020152CrossrefMedlineGoogle Scholar9. Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging.Front Oncol. 2011; 1:58. doi: 10.3389/fonc.2011.00058MedlineGoogle Scholar10. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma.J Clin Oncol. 2005; 23:8812–8818. doi: 10.1200/JCO.2005.03.1484CrossrefMedlineGoogle Scholar11. Leestma JE, Price EBParaganglioma of the urinary bladder.Cancer. 1971; 28:1063–1073.CrossrefMedlineGoogle Scholar12. Beilan JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature.BMC Urol. 2013; 13:22. doi: 10.1186/1471-2490-13-22CrossrefMedlineGoogle Scholar13. Zimmerman IJ, Biron RE, Macmahon HE. Pheochromocytoma of the urinary bladder.N Engl J Med. 1953; 249:25–26. doi: 10.1056/NEJM195307022490106CrossrefMedlineGoogle Scholar14. Loveys FW, Pushpanathan C, Jackman S. Urinary bladder paraganglioma: AIRP best cases in radiologic-pathologic correlation.Radiographics. 2015; 35:1433–1438. doi: 10.1148/rg.2015140303CrossrefMedlineGoogle Scholar15. Zhai H, Ma X, Nie W, Li H, Peng C, Li X, Zhang Y, Zhang X. Paraganglioma of the urinary bladder: a series of 22 cases in a single center.Clin Genitourin Cancer. 2017; 15:e765–e771. doi: 10.1016/j.clgc.2017.03.010CrossrefMedlineGoogle Scholar16. Hanji AM, Rohan VS, Patel JJ, Tankshali RA. Pheochromocytoma of the urinary bladder: a rare cause of severe hypertension.Saudi J Kidney Dis Transpl. 2012; 23:813–816. doi: 10.4103/1319-2442.98167CrossrefMedlineGoogle Scholar17. Park S, Kang SY, Kwon GY, et al. Clinicopathologic characteristics and mutational status of succinate dehydrogenase genes in paraganglioma of the urinary bladder: a multi-institutional Korean study.Arch Pathol Lab Med. 2017; 141:671–677. doi: 10.5858/arpa.2016-0403-OACrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wu C, Yang X, Zhang H, Song Y, Xaplanteris P, Ferrannini G, Asher E, Tindale A and Thomson R (2021) Cardiac paraganglioma with sulfur subunit B gene mutation: a case report, European Heart Journal - Case Reports, 10.1093/ehjcr/ytab025, 5:2, Online publication date: 4-Feb-2021. Dominiczak A and Meyer T (2019) Hypertension, Hypertension, 75:1, (3-4), Online publication date: 1-Jan-2020. November 2019Vol 74, Issue 5 Advertisement Article InformationMetrics © 2019 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.119.13140PMID: 31564165 Originally publishedSeptember 30, 2019 PDF download Advertisement

A Woman with Treatment-Resistant Hypertension

A Rare Disease Leading to Hypertension.

RESISTANT HYPERTENSION: WHEN DRUG THERAPY IS THE CULPRIT

Paroxysmal Hypertension Associated with Urination

Proximal Renal Artery Stenosis Presenting as Uncontrolled Hypertension

Blood Pressure Lowering in Patients With Central Hypertension: A randomized Clinical Trial

Medical Measures in Hypertensives Considered Resistant

Response to Masked Hypertension in Untreated and Treated Patients with Diabetes Mellitus: Attractive but Questionable Interpretations and Response to is Masked Hypertension Related to Diabetes Mellitus?

Clinical Characteristics, Antihypertensive Medication Use and Blood Pressure Control among Patients with Treatment-Resistant Hypertension: the Survey of PatIents with Treatment ResIstant Hypertension Study

Diagnosis and management of resistant hypertension

Controversies in Hypertension V: Resistant and Refractory Hypertension

Hypertension in Patients with Diabetes: Questions

Strategy for the treatment of noncompliant hypertensive hemodialysis patients

Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements

A physiologic, precision-medicine approach to guided pharmacological treatment of hypertension substantially improves blood pressure in a large community-based cohort

8437 Improved Quality Of Life&Blood Pressure Following Diagnosis And Medical Management Of Primary Aldosteronism (PA) / Georgian Experience

Options for patients with out-of-control blood pressure: after all avenues have been exhausted

A16395 Hypertension Management and Effect Analysis on Treatment Flow Path in the Uncontrolled Blood Pressure Patients of Community Health Center

Abstract P190: Management Of Patients With Hypertension: Challenges From A Student-Run Free Clinic

Systematic Review Article: New Drug Strategies for Treating Resistant Hypertension-the Importance of a Mechanistic, Personalized Approach

745 INTERDISCIPLINARY EVALUATION IN RESISTANT ARTERIAL HYPERTENSION